These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1941882)

  • 21. Abnormal structure and function of isolated subcutaneous resistance vessels from essential hypertensive patients despite antihypertensive treatment.
    Aalkjaer C; Eiskjaer H; Mulvany MJ; Jespersen B; Kjaer T; Sørensen SS; Pedersen EB
    J Hypertens; 1989 Apr; 7(4):305-10. PubMed ID: 2723429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term structural changes in human hypertensive vessels.
    Heagerty AM; Bund SJ; Izzard AS
    Basic Res Cardiol; 1991; 86 Suppl 1():19-23. PubMed ID: 2036092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The primary and secondary prevention of hypertensive cardiopathy].
    Agabiti-Rosei E; Muiesan ML
    Ital Heart J; 2000 Jun; 1 Suppl 2():59-66. PubMed ID: 10905130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of vascular structural changes and calcium metabolism in patients with essential hypertension after long-term monotherapy with enalapril.
    Ueno H; Takata M; Oh-hashi S; Tomoda F; Yasumoto K; Iida H; Sasayama S
    J Hum Hypertens; 1993 Apr; 7(2):125-30. PubMed ID: 8510084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heart and vessel hypertrophy in hypertension: possibilities of regression.
    Cífková R; Niederle P; Romanovská L; Skibová J; Frídl P; Skalická H; Widimský J
    J Hypertens Suppl; 1987 Dec; 5(5):S407-10. PubMed ID: 2965227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of angiotensin converting enzyme inhibition on vascular remodelling of resistance vessels in hypertensive patients.
    Mulvany MJ
    J Hypertens Suppl; 1996 Dec; 14(6):S21-4. PubMed ID: 9023711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural regression of the vasculature during antihypertensive treatment.
    Jern S; Sivertsson R
    J Clin Hypertens; 1987 Sep; 3(3):355-9. PubMed ID: 3668595
    [No Abstract]   [Full Text] [Related]  

  • 28. Hypertension in obesity.
    Redon J
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):344-53. PubMed ID: 11887431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural changes during the early onset of experimental hypertension: trophic influences of the renin-angiotensin system.
    Morton JJ; Beattie EC; Griffin SA; MacPherson F
    J Hum Hypertens; 1991 Aug; 5 Suppl 1():9-14. PubMed ID: 1941884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lisinopril in the treatment of hypertension.
    Messerli FH; Kaesser UR
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():17-21. PubMed ID: 2550640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural and functional adaptation in the rat myocardium and coronary vascular bed caused by changes in pressure and volume load.
    Friberg P
    Acta Physiol Scand Suppl; 1985; 540():1-47. PubMed ID: 3161269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypertension and the arterial system: clinical and therapeutic aspects.
    Safar ME; Levy BI; Laurent S; London GM
    J Hypertens Suppl; 1990 Dec; 8(7):S113-9. PubMed ID: 2095379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Isolated systolic hypertension as risk factor. Also in this case lowering blood pressure makes sense].
    Offers E; Kolloch R
    MMW Fortschr Med; 2000 Nov; 142(47):26-8. PubMed ID: 11143775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Changes of arterial bed in essential hypertension and treatment policy].
    Gogin EE
    Ter Arkh; 1999; 71(1):64-7. PubMed ID: 10097306
    [No Abstract]   [Full Text] [Related]  

  • 35. New insights into molecular mechanisms of hypertension.
    Burger D; Nishigaki N; Touyz RM
    Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):160-2. PubMed ID: 20098323
    [No Abstract]   [Full Text] [Related]  

  • 36. Vasoprotection and antihypertensive therapy.
    Henry PD; Cabello OA
    Curr Opin Nephrol Hypertens; 1995 Mar; 4(2):197-200. PubMed ID: 7600051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are vascular abnormalities a primary cause or secondary consequence of hypertension?
    Mulvany MJ
    Hypertension; 1991 Sep; 18(3 Suppl):I52-7. PubMed ID: 1889858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural adaptation of the cardiovascular system in hypertension. Hemodynamic consequences of vascular wall hypertrophy.
    Sivertsson R
    Nephron; 1987; 47 Suppl 1():71-5. PubMed ID: 3696354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey.
    Christensen KL; Mulvany MJ
    J Hypertens; 2001 Jun; 19(6):1001-6. PubMed ID: 11403346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular remodelling in hypertension.
    Mulvany MJ
    Eur Heart J; 1993 Jul; 14 Suppl C():2-4. PubMed ID: 8365424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.